TheraCryf plc (AIM: TCF), the AIM-listed biotechnology company developing medicines for addiction and neuropsychiatric disorders, has announced participation in two investor conferences in London during November 2026. Chief Executive Officer Dr Huw Jones presented at the LSX Investival Showcase at Old Billingsgate on 16 November 2026, while the company will also attend Mello London on 17 and 18 November. The events give existing shareholders and prospective investors the opportunity to hear directly about TheraCryf's lead Ox-1 addiction programme, which the company describes as a novel, best-in-class orexin-1 receptor antagonist.

Key Points

  • TheraCryf plc (AIM: TCF) — AIM-listed biotechnology company headquartered at Alderley Park, Cheshire
  • Management presenting at LSX Investival Showcase on 16 November and Mello London on 17–18 November 2026
  • Presentations will draw only on information already in the public domain; no new material information will be disclosed
  • Investors may be watching for updates on regulatory submissions for first-in-man studies, targeted for 2026

Dr Huw Jones Presents TheraCryf's Ox-1 Programme at Old Billingsgate on 16 November 2026

Dr Huw Jones, Chief Executive Officer, delivered a presentation at the LSX Investival Showcase held at Old Billingsgate, London, at 11.45 am on 16 November 2026. The showcase provides a platform for life sciences companies to engage institutional and retail investors. TheraCryf's presentation focused on its lead orexin-1 receptor antagonist programme, which is being developed as a potential treatment for addiction, including binge eating disorder, alcohol use disorder, and other substance use disorders — conditions the company identifies as areas of significant unmet medical need.

TheraCryf's Two Mello London Sessions Scheduled for Clayton Hotel, Chiswick

TheraCryf will present at Mello London at the Clayton Hotel and Conference Centre in Chiswick across two sessions: from 10.40 to 11.10 am on Tuesday, 17 November 2026, and from 2.25 to 2.55 pm on Wednesday, 18 November 2026. The company has made available a 25% discount code — SHAREML25 — for investors wishing to attend. The announcement confirms that management will be available for meetings with both existing shareholders and prospective investors at these events, providing direct access to the leadership team including CEO Dr Huw Jones, CFO Toni Hänninen, and COO Dr Helen Kuhlman.

BIO-Europe Cologne Attendance Preceded the London Conference Schedule

The London investor conference appearances follow TheraCryf's attendance at BIO-Europe in Cologne from 9 to 11 November 2026, where management held meetings with potential partners and industry colleagues to discuss the company's development programmes. TheraCryf operates a capital-light, virtual development model, advancing programmes to early clinical or proof-of-concept stage before seeking to partner with larger pharmaceutical and biotechnology companies. The Ox-1 programme is described as fully funded through final pre-clinical trials to clinical readiness, with regulatory submissions for first-in-man studies targeted for 2026.

TheraCryf's Pipeline Beyond Ox-1 Includes DAT Modulator and Glioblastoma Programmes

Beyond its lead addiction programme, TheraCryf is developing a dopamine transporter modulator programme targeting fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy, and narcolepsy. The group also holds a legacy grant-funded oncology programme in glioblastoma using SFX-01. The company stated explicitly that the investor conference presentations will draw solely on information already in the public domain and that no new material information will be disclosed, a standard regulatory precaution for AIM-listed companies ahead of investor-facing events.